Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | AZD1775: Aiding in the treatment of glioblastomas

Manmeet Ahluwalia • 2 Jun 2017
ASCO 2017
Head and Neck Cancer AZD1775 Temozolomide

Manmeet Singh Ahluwalia, MD, from the Cleveland Clinic, Cleveland, OH, talks to us about his team’s research on glioblastoma and AZD1775, a WEE1 inhibitor that acts to make tumour cells more susceptible to destruction by chemotherapy and radiation. Current clinical trials on the drug are focused on investigating the safe dose for the drug in combination with radiation therapy and temozolomide (NCT01849146) and Phase II trials are planned for evaluating the efficacy of the combination regimen in treating glioblastomas. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.

More from Manmeet Ahluwalia

The emergence of targeted therapies and ICIs for brain metastasis
1:23
The emergence of targeted therapies and ICIs for brain metastasis
Manmeet Ahluwalia • 30 May 2025
DART: nivolumab and ipilimumab in rare cancers and brain metastases
2:33
DART: nivolumab and ipilimumab in rare cancers and brain metastases
Manmeet Ahluwalia • 30 May 2025
Assessing MB-FUS in the LIMITLESS and LIBERATE trials
2:40
Assessing MB-FUS in the LIMITLESS and LIBERATE trials
Manmeet Ahluwalia • 30 May 2025
Transformative potential of CAR-T cell therapy: current challenges and future Directions
3:17
Transformative potential of CAR-T cell therapy: current challenges and future Directions
Manmeet Ahluwalia • 8 Mar 2024

Related Videos

IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
0:34
IMRT deintensification in early-stage oropharyngeal cancer: insights from the JCOG1208 trial
Satoaki Nakamura • 16 May 2026
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
0:41
Considerations for HPV status in the JCOG1208 trial of IMRT in early-stage oropharyngeal cancer
Satoaki Nakamura • 16 May 2026
Can IMRT alone be used for higher-risk oropharyngeal cancer?
0:42
Can IMRT alone be used for higher-risk oropharyngeal cancer?
Satoaki Nakamura • 16 May 2026
Could cemiplimab replace HHI therapy in BCCHN?
0:36
Could cemiplimab replace HHI therapy in BCCHN?
Hannah Kenny • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals